Frontiers in Microbiology (Oct 2021)

Bifidobacterial β-Galactosidase-Mediated Production of Galacto-Oligosaccharides: Structural and Preliminary Functional Assessments

  • Valentina Ambrogi,
  • Valentina Ambrogi,
  • Francesca Bottacini,
  • Francesca Bottacini,
  • John Mac Sharry,
  • John Mac Sharry,
  • John Mac Sharry,
  • Justin van Breen,
  • Ellen O’Keeffe,
  • Dan Walsh,
  • Barry Schoemaker,
  • Linqiu Cao,
  • Bas Kuipers,
  • Cordula Lindner,
  • Maria Luisa Jimeno,
  • Elisa G. Doyagüez,
  • Oswaldo Hernandez-Hernandez,
  • F. Javier Moreno,
  • Margriet Schoterman,
  • Douwe van Sinderen,
  • Douwe van Sinderen

DOI
https://doi.org/10.3389/fmicb.2021.750635
Journal volume & issue
Vol. 12

Abstract

Read online

In the current study the ability of four previously characterized bifidobacterial β-galactosidases (designated here as BgaA, BgaC, BgaD, and BgaE) to produce galacto-oligosaccharides (GOS) was optimized. Of these enzymes, BgaA and BgaE were found to be promising candidates for GOS production (and the corresponding GOS mixtures were called GOS-A and GOS-E, respectively) with a GOS concentration of 19.0 and 40.3% (of the initial lactose), respectively. GOS-A and GOS-E were partially purified and structurally characterized. NMR analysis revealed that the predominant (non-lactose) disaccharide was allo-lactose in both purified GOS preparations. The predominant trisaccharide in GOS-A and GOS-E was shown to be 3′-galactosyllactose, with lower levels of 6′-galactosyllactose and 4′-galactosyllactose. These three oligosaccharides have also been reported to occur in human milk. Purified GOS-A and GOS-E were shown to be able to support bifidobacterial growth similar to a commercially available GOS. In addition, GOS-E and the commercially available GOS were shown to be capable of reducing Escherichia coli adhesion to a C2BBe1 cell line. Both in vitro bifidogenic activity and reduced E. coli adhesion support the prebiotic potential of GOS-E and GOS-A.

Keywords